Clinical trials: Refractive Error - Myopia Bilateral
Myopia, Hyperopia
Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses
Bilateral dispensing clinical trial of fanfilcon A toric lens verses enfilcon A toric lens over two weeks.
- Conditions
- Myopia, Hyperopia, Astigmatism
- Trial name
- NCT02423109
- Testing
- fanfilcon A, enfilcon A
- Where
- 2 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- CooperVision, Inc.
Refractive Error - Myopia Bilateral
Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens
This clinical study is to provide clinical performance data comparing the test lens (Deseyne [vifilcon C] daily disposable soft contact lens) to a control lens (1-Day Acuvue Moist [etafilcon A] daily disposable soft contact lens)…
- Trial name
- NCT05927753
- Testing
- Deseyne Daily Disposable Contact Lens (Test Device)
- Where
- 3 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Bruno Vision Care
Myopia, Hyperopia
A Bilateral Dispensing Clinical Trial of Sapphire Lens Against Senofilcon A Lens Over 2 Weeks
To evaluate the clinical performance of an investigational silicone-hydrogel lens when worn on a daily wear modality over two weeks of lens wear.
- Trial name
- NCT02345811
- Testing
- Sapphire, senofilcon A
- Where
- 2 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- CooperVision, Inc.
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease…
- Trial name
- OLIMPIC (NCT02034006)
- Testing
- Ranibizumab
- Where
- 31 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals